Tyverb

Pharma industry R&D pipelines

pharmafile | February 16, 2011 | Feature | Research and Development |  pipeline, pipelines 

 

New medicines which advance the treatment of diseases are the lifeblood of the pharmaceutical industry, and billions are invested by the sector every year in discovering and developing breakthrough drugs.

The industry is currently undergoing a crisis in its in-house R&D productivity, however, increasing investment in discovery and development has, in recent year, produced diminishing returns.

‘Big Pharma’ is now looking at new ways of conducting R&D to ensure more breakthrough drugs are discovered more quickly, and at less cost, while meeting demands for safety and efficacy data.

Advertisement

The following are links to the combined pipelines of the industry’s top 10 companies in specific disease areas.

 

Phase III

The final stage of a drug’s development, phase III involves large scale trials of the drug in the patients who can benefit from them.

Oncology

The development of new cancer drugs has become the industry’s single most important area in recent years, led by new insights into how different cancers work, and the need to improve on existing treatments, which offer limited extension in life and sometimes bring with them serious side effects.

Related Content

roche__tree

From pipeline to patients: Navigating treatments through the UK system

Pharmafocus spoke to Karen Lightning-Jones, Integrated Franchise Leader, Pipeline, to discuss the current UK climate …

lilly_entrance_web

Eli Lilly showcases emerging pipeline to investors

Eli Lilly and Co (NYSE: LLY) has showcased its emerging pipeline to potential investors, highlighting …

tug-of-war

Focus: Medivation tug-of-war rumbles on

Medivation (NASDAQ: MDVN) has been making all the headlines as a list of suitors’ line …

The Gateway to Local Adoption Series

Latest content